MarketVIEW: Ross River Virus vaccines - WTVM.com-Columbus, GA News Weather & Sports

MarketVIEW: Ross River Virus vaccines

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, July 7, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

MarketVIEW: Ross River Virus vaccines

http://www.reportbuyer.com/pharma_healthcare/therapeutic/marketview_ross_river_virus_vaccines.html

Ross River Virus (RRV) is a mosquito-borne alphavirus (Togaviridae) mainly indigenous to Australia and the Western Pacific region. Infection with the virus can cause joint pain (polyarthritis/arthralgia) in humans which is reported to persist from between 3 months to a year or more. There is no cure for RRV disease, and treatment is confined to the management of pain. In Australia, several thousand cases occur each year with variability across territories.

Due to its high morbidity and impact on quality of life, Baxter Bioscience mainly in concert with Queensland University of Technology, Brisbane have been developing and inactivated Ross River virus vaccine. A first Phase 3 study started in male and female subjects aged >16 years initiated in April 2011 with licensure predicted in 1-2 years.

This MarketVIEW product is a comprehensive commercial opportunity assessment detailing the potential market for a Ross River virus vaccine with a patient based value/volume forecast for all Australians and "at risk" areas only to 2030. The potential use of the vaccine in travelling populations is also explored along with a review of latest epidemiology, clinical development update and rationale for vaccine approach.

THIS PRODUCT IS COMPOSED OF SUMMARY PRESENTATION + 1 MODEL (optional)
Contents – Summary presentation (MS PowerPoint based)

Authors Note
Executive summary
Ross River virus vaccine: key mode outputs
Ross River virus vaccine: predicted market to 2030 ($ 000s)
Ross River virus vaccine: predicted volume to 2030 (doses 000s)
Ross River virus vaccine: predicted market to 2030 ($ 000s) – risk areas
Ross River virus vaccine: predicted volume to 2030 (doses 000s) – risk areas
Ross River virus vaccine: predicted travel market to 2030 ($ 000s)
Ross River virus vaccine: predicted travel volume to 2030 ($ 000s)
Ross River virus: Disease background and epidemiology
Ross River virus: geography/countries affected
Ross River virus: historical outbreaks and epidemics 1979 to 1980
Ross River virus: increasing reports of epidemics 1886 to 1998
Ross River virus: current risk map of infection in Australia
Ross River virus: number of notifications (Australia) to 2012
Notifications and notification rates of Ross River virus infections, Australia, 2006-07 by Statistical Division of residence
Ross River virus: notification rates in select jurisdictions 2006-07
Ross River virus: notifications Western Australia, 2011
Ross River virus: notifications Queensland, 1997-2006
Ross River virus: notifications Queensland, 1997-2006 (per district)
Ross River virus: notifications Victoria, 1998-2009
Ross River virus: notifications South Australia, 1992-2003
Ross River virus: New South Wales: 2009-2013
Ross River virus: Tasmania
Ross River virus: notes on transmission
Ross River virus: mosquito vectors
Ross River virus: vertebrate hosts
Ross River virus: diagnosis/antibody prevalence
Ross River virus: clinical aspects
Ross River virus: age/gender of infections
Ross River virus: joint involvement in RRV disease
Ross River virus: economic burde
Ross River virus: importation and spread to other countries
Ross River virus: future trends – climate
Ross River virus: future trends - human and environment interactions
Ross River virus: Summary of vaccine development
Ross River virus: rationale for vaccine development
Ross River virus vaccine: Baxter Bioscience/Univ Queensland
Ross River virus: Phase 1/2 clinical data
Ross River virus: Phase 3 study design
Ross River virus: Six-month safety follow-up study/approval
Ross River virus: antibody-dependent enhancement
Ross River virus vaccine: Modelling commercial potential
Ross River virus vaccine: target product profile (TPP)
RRV vaccine: modelling strategy (endemic Australia)
RRV vaccine penetration rates per territory (Australia)
RRV vaccine: modelling strategy (travellers)
Western travelers: major commercial model assumptions
Travellers to Australia
RRV vaccine: schedule considerations for travelers segment
Example penetration rates of travel vaccines
Bibliography
Disclaimer
About VacZine Analytics

PAGES: 64 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model(s) (MS Excel-based) – 1 model

Title sheet
CHARTS – AUST (comb)
CHARTS – endemic Aust (all)
CHARTS – endemic Aust (risk)
CHARTS – travellers
Travel summary
Aust endemic (all) summary
Aust endemic (risk) summary
Endemic use
Australia >16 yrs (all)
New South Wales
Victoria
Queensland
West Australia
Tasmania
Northern Territory
Australian capital
Australia >16 yrs (risk)
New South Wales
Victoria
Queensland
West Australia
Tasmania
Northern Territory
Australian capital
Travel use
US/Canada – Travellers
EU – Travellers
ROW – Travellers
Source material
Number of cases (Aust)
Hosts
Mosquito vectors
Population (Australia)
Territories total data
Territories risk areas
Travellers per territory.
International travellers
Back page

WORKSHEETS: ~65

Read the full report:
MarketVIEW: Ross River Virus vaccines

http://www.reportbuyer.com/pharma_healthcare/therapeutic/marketview_ross_river_virus_vaccines.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

1909 Wynnton Road
Columbus, Ga. 31906

FCC Public File
publicfile@wtvm.com
706-494-5400
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and WTVM. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.